LogicBio Therapeutics, Inc. Common Stock
LOGC
LOGC was delisted on the 15th of November, 2022.
46 hedge funds and large institutions have $8.66M invested in LogicBio Therapeutics, Inc. Common Stock in 2022 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 6 increasing their positions, 14 reducing their positions, and 14 closing their positions.
19% less funds holding
Funds holding: 57 → 46 (-11)
57% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 14
71% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 14
77% less capital invested
Capital invested by funds: $37M → $8.66M (-$28.3M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$504K |
| 2 |
VF
Virtu Financial
New York
|
+$59.4K |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
+$55.2K |
| 4 |
Bank Julius Baer & Co
Zurich,
Switzerland
|
+$21.3K |
| 5 |
FT
Fiduciary Trust
Boston,
Massachusetts
|
+$11K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SC
Samlyn Capital
New York
|
-$3.49M |
| 2 |
Franklin Resources
San Mateo,
California
|
-$752K |
| 3 |
PIM
Platinum Investment Management
Sydney Australia 2000,
Australia
|
-$740K |
| 4 |
EP
Eversept Partners
New York
|
-$672K |
| 5 |
PVI
Pura Vida Investments
New York
|
-$532K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Walleye Capital
New York
| – | -$25K | -10,924 | Closed |
|
52
Simplex Trading
Chicago,
Illinois
| – | -$10.6K | -9,686 | Closed |
|
53
UBS Group
Zurich,
Switzerland
| – | -$17K | -7,561 | Closed |
|
54
JP Morgan Chase
New York
| – | -$1K | -344 | Closed |
|
LOGC Hedge Fund Activity: Q1 2022 in Review
46 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in LogicBio Therapeutics, Inc. Common Stock (LOGC) for Q1 2022, worth a combined $8.66M — down 77% from $37M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of LOGC and 4 opened new positions — a net loss of 10 holders — while 14 trimmed existing stakes and 6 added.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $504K. The largest seller was Samlyn Capital, exiting entirely with an estimated $3.49M sold.
- 46 institutional investors held LogicBio Therapeutics, Inc. Common Stock (LOGC) as of Q1 2022, down from 57 in Q4 2021.
- Funds reported $8.66M of LogicBio Therapeutics, Inc. Common Stock stock for Q1 2022, down 77% quarter-over-quarter.
- 4 funds opened new LogicBio Therapeutics, Inc. Common Stock positions in Q1 2022 and 14 closed out, a net change of -10 holders.
- The largest LogicBio Therapeutics, Inc. Common Stock buyer in Q1 2022 was Renaissance Technologies, an estimated $504K added.
- The largest LogicBio Therapeutics, Inc. Common Stock seller in Q1 2022 was Samlyn Capital, an estimated $3.49M sold.
Based on aggregated 13F filings for Q1 2022.